الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 77 |  |  |
| | | from | 77 | | |
Abstract
Bacterial conjunctivitis is a common, acute, contagious disease characterized by inflamed conjunctiva with purulent mattering of the lids. Topical antibiotics have been shown to speed clinical recovery. Since cultures are rarely performed, the treatment is
typically empiric with broad spectrum topical antibiotics. This practice is supported by
studies previously showing clinical conjunctivitis is caused by a bacterial organism between
55% and 78% of the time.
Moxifloxacin 0.5% ophthalmic solution is a fourth-generation fluoroquinolone currently indicated for 13 isolates of bacterial conjunctivitis. It is a broad spectrum, concentration-dependent, bactericidal antibiotic. Conversely, azithromycin is derived from the parent class of macrolides known to be bacteriostatic and time dependent. While it is suggested that concentration is a factor in the antibacterial effect of azithromycin, given the current high level of Gram-positive resistance patterns, this agent demonstrates a time-dependent, bacteriostatic effect. Azithromycin 1.5% is currently indicated for 5 bacterial isolates.
In this study we aimed to evaluate the effect of Azithromycin 1.5 % eyedrops versus Moxifloxacin 0.5 % eyedrops in treatment of bacterial conjunctivitis.
100 patients with purulent bacterial conjunctivitis, defined by mild to severe bulbar conjunctival injection and purulent discharge in at least one eye.
They were divided into 2 groups 50 in each group (one group receive Azithromycin 1.5% eye drops twice daily for 7 days and the other receive Moxifloxacin 0.5% eye drops 3 times per day for 7 days).
Patient was 6 years of age or older (male or female) with mucopurulent or purulent discharge and with bulbar conjunctival injection.
We exclude patient who contact lens wearers, patient with bacterial conjunctivitis more than 7 days earlier, any patient associated with Trauma or foreign body, dacryocystiti, keratitis, viral ocular infection, significant ocular abnormality and amblyopia. Any pregnant women, diabetic patients, hepatic patients, renal patients and systemic or ocular antibiotics, anti-inflammatory or immune-suppressive treatments.